FDA Orders Juul Products to Be Removed from Retailers

Jul.01.2022
FDA Orders Juul Products to Be Removed from Retailers
FDA tried to order retailers to remove Juul products but a federal appeals court suspended the order, citing contrasting arguments.

If the U.S. Food and Drug Administration (FDA) has its way, one of the largest electronic cigarette retailers in the country may be forced out of business. Last Thursday, the FDA began sending letters to retailers ordering them to remove all Juul products from their shelves. The following day, a federal appeals court temporarily suspended the FDA's order, allowing Juul to continue selling its products while the court hears arguments from both sides.

 

The FDA is alleging that Juul has not provided "sufficient evidence regarding the toxicological characteristics of their products to demonstrate that their marketing is appropriate for protecting public health." In response, Juul released a statement calling the FDA's ban "arbitrary and capricious.

 

Is Juuling on the way out?

 

This week, health reporter for Time, Jamie Ducharme argued that the ban on Juul may not be the public health victory that people have imagined, and pointed out that "adult smokers also use Juul for smoking cessation - last week's decision was not a victory for them.

 

Tim Andrews from the US Tax Reform Organization also wrote in the Washington Post that taking Juul products off the market "will cut off a proven method that helps millions of smokers quit, leading to more smoking and more deaths." As evidence, Andrews cited comments "consistently finding e-cigarettes two to six times more effective than other cessation devices" and a study by Georgetown University Medical Center, which estimated that e-cigarettes could save the lives of up to 6.6 million Americans who would live at least 10 years longer.

 

Jonathan Foulds, a professor of public health sciences at Pennsylvania State University, agrees with this sentiment, stating on Twitter that "banning smoking from these life-saving exits because of 'potentially harmful chemicals' that may exude from some pods is a bit like locking the fire escape door because the steps might be slippery.

 

What's worse, Zule or cigars?

 

In his article for the Washington Post, Tim Andrews cited a "meta-analysis" of scientific research on e-cigarettes, commissioned by the UK government and "replicated by external medical institutions," which concluded that e-cigarettes are "95% safer than combustible tobacco." Bloomberg reporters Fiona Rutherford and Robert Langreth acknowledged that "some evidence suggests that e-cigarettes are a safer option than smoking," but claim that "there is not enough long-term data to draw a definitive conclusion." It is worth noting that Michael Bloomberg is a major funder of the campaign to ban flavored e-cigarette products.

 

From April 2019 to February 2020, the US experienced an outbreak of lung injuries related to the use of electronic cigarettes or vaping products, known as EVALI, resulting in 2,807 hospitalizations and 68 deaths. Of note, 82% of hospitalized patients reported using marijuana while only 14% reported nicotine use alone. The Centers for Disease Control and Prevention also found that many of the deaths or hospitalizations were linked to the use of unregulated black-market THC products in their vaping devices. In comparison, smoking is estimated to cause 480,000 deaths per year in the US.

 

However, electronic cigarettes may not be the healthy alternative that some supporters claim. The Johns Hopkins School of Medicine notes that electronic cigarettes have not been approved by the Food and Drug Administration as a smoking cessation device, and "recent research has found that the majority of people who intended to use electronic cigarettes to quit nicotine habit ended up continuing to use both traditional cigarettes and e-cigarettes.

 

Just think about the children!

 

In 2018, 30% of American high school students "reported having tried nicotine at least once in the past year," according to a cover story by Jamie Ducharme in TIME magazine in 2019. This is the largest increase in substance use in at least 44 years. The 2018 report by the National Academy of Sciences also showed that children who use e-cigarettes are more likely to try traditional cigarettes. Although the FDA's decision did not specifically address the relationship between Juul and youth e-cigarette use, as reported by the New York Times, "public health experts and legislators continue to express concern about the addition of nicotine to some e-cigarettes that remain on the market, including brands like PuffBar that offer fruit flavors that are attractive to young people.

 

However, the theory still remains debatable. Writing for a conservative independent women's forum, Lindsey Stroud argues that Juul does not encourage children to smoke. According to a public opinion survey, she wrote, "From 2019 to 2021, the usage of Juul products among 12th-grade students decreased by 46.9% in the past 30 days. Additionally, in 10th-grade students, the number of people using JUUL decreased by 75.3% during that time." The editorial board of The New York Daily News agreed, writing that Juul "has largely lost favor with teenage consumers" in recent years. However, all of this may just be a passing trend, like water vapor evaporating in the wind.

 

Source: The Week

 

This article contains excerpts or reprints of third-party information. The copyright of the reproduced information belongs to the original media and author.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
Indonesia’s BNN Pushes Total Vape Ban as Health Ministry Tightens Tobacco Packaging Rules, Putting $40 Billion Industry at Risk
Indonesia’s BNN Pushes Total Vape Ban as Health Ministry Tightens Tobacco Packaging Rules, Putting $40 Billion Industry at Risk
Indonesia is entering a new phase of debate over vape and tobacco regulation. The National Narcotics Agency (BNN) has proposed a total vape ban, with some lawmakers supporting stronger restrictions. At the same time, the Health Ministry is advancing tobacco and nicotine regulations under Government Regulation No. 28/2024, including measures such as plain packaging and product controls. Tobacco and vape industries have warned that tighter rules could affect a sector worth around $40 billion, supporting about 6 million jobs and contributing significant tax revenue.
Jul.27
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
JAMA Study: U.S. Vape Directories Fail to Sustainably Curb Unlisted Sales as Product Shifts May Redistribute Brand Share 2Firsts Recommended
A study by CDC Foundation researchers found no sustained decline in e-cigarette sales across Alabama, Oklahoma and Louisiana, the first three U.S. states to implement e-cigarette directory laws. Louisiana initially saw a significant sales decline, followed by a rebound and a persistent reduction in product availability. Sales also shifted from nontobacco-flavored disposables toward prefilled cartridges, with Vuse Alto driving much of the increase in menthol cartridges. By April 2025, unlisted products still accounted for more than half of e-cigarette nicotine sales in all three states.
Sep.18
PMI Global R&D Chief Meets Chinese Tobacco Regulator as China Advances Heated Cigarette Standards
PMI Global R&D Chief Meets Chinese Tobacco Regulator as China Advances Heated Cigarette Standards
Philip Morris International’s global R&D chief Michele Cattoni met Liu Sanjiang, deputy director of China’s State Tobacco Monopoly Administration, in Beijing on Aug. 27. The meeting comes as China advances mandatory standards for heated cigarettes and nicotine pouches, laying groundwork for their domestic introduction. Cattoni has held senior roles in PMI’s heated tobacco development, while China’s draft standard covers multiple heating architectures, including systems similar in principle to PMI’s IQOS ILUMA technology.
Aug.27